



## WEDNESDAY 23 MARCH

17.00-18.30 **Satellite Symposium - Eli Lilly** (Auditorium 2)

17.00-18.30 **ESCEO-FROMO Symposium**  
(ESCEO room 1 - 1<sup>st</sup> floor)

**Rheumatic diseases and bone** - Chairman: C. Cooper

- *Bone and arthritides: New developments in the osteo-immunology arena* - J.-P. David
- *Therapeutic targets for bone changes in inflammatory arthritis* - J. Louie
- *Systemic lupus erythematosus, cytokines and bone* - A. Chines
- *New perspectives in the registration of drugs for rheumatoid arthritis* - B. Avouac
- *Biomarkers in the diagnosis, monitoring and prognosis of rheumatoid arthritis* - P. Miossec

18.50-21.00 **Opening Ceremony**

**Chairs:** J.A. Kanis - J-Y. Reginster

18.50-19.50 **Servier Honorary Lecture** (Auditorium 1)

**Skeletal involvement in the pathogenesis and outcomes of rheumatoid arthritis and osteoarthritis** - J-P. Pelletier

19.50-20.00 **Presentation of the ESCEO-IOF Servier Pierre D. Delmas Prize**

20.00-20.05 **Presentation of the ESCEO-IOF Herbert Fleisch Medal in recognition of outstanding achievement in basic research**

20.05-21.00 **Welcome Cocktail**  
Courtesy of Rottapharm | Madaus

## THURSDAY MARCH 24

09.00-11.50 **Scientific Session I** (Auditorium 1)

**Chairs:** R. Rizzoli - E. McCloskey

09.00-09.30 **Plenary Lecture 1**

**Osteoporosis and burden of diseases** - N. Freemantle

09.30-09.40 **Presentation of the ESCEO-Amgen Fellowship Awards**

09.40-09.50 **Presentation of the ESCEO Young Investigator Awards supported by a grant from MSD**

09.50-10.20 **Oral Communications**

09:50-10:00 **OC1**

*The burden of fractures in France, Germany, Italy, Spain, Sweden and the UK* - Q. Ström, F. Borgström, J.A. Kanis, B. Jönsson

10.00-10.10 **OC2**

*Bone microarchitecture assesment by high-resolution peripheral quantitative computed tomography (HR-pQCT) in healthy women* - M. Zanchetta, C. Monteverde, F. Silveira, V. Ripero, C. Bogado, J. Zanchetta

10.10-10.20 **OC3**

*DAPS (Denosumab Adherence Preference Satisfaction): results of the second year of the crossover study* - N. Freemantle, D. Kendler, P. Kaur, S. Siddhanti, E. Tang, D. Macarios, S. Satram-Hoang, J. Borenstein, M. McClung

10.20-10.50 **Plenary Lecture 2**

**Non invasive evaluation of bone strength** - R. Müller

10.50-11.50 **Oral Communications**

10.50-11.00 **OC4**

*Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis* - A. Moayyeri, J. Adams, R. Adler, G. Blake, M-A. Krieg, D. Hans, J. Compston, E.M. Lewiecki

11.00-11.10 **OC5**

*Force directions for optimal proximal femoral strength and hip fracture risk assessment in men and women: the AGES-Reykjavik study* - J. Keyak, B. Jonsson, K. Siggeirsdottir, G. Eiriksdottir, V. Gudnason, T. Lang, S. Sigurdsson, G. Karlsdottir, D. Oskarsdottir, A. Sigmarsdottir, S. Zhao, J. Kornak, T. Harris, G. Sigurdsson

11.10-11.20 **OC6**

*Local topological analysis at the distal radius by HR-pQCT: application to in vivo bone microarchitecture and fracture assessment in the OFELY study* - J-B. Pialat, N. Vilayphiou, S. Boutroy, P-J. Gouttenoire, E. Sornay-Rendu, R. Chapurlat, F. Peyrin

11.20-11.30 **OC7**

*Clinical risk factors, bone mineral density and falls history in the prediction of incident fracture among men and women* - M. Edwards, K. Jameson, H. Denison, A.A. Sayer, C. Cooper, E. Dennison



## ECCEO11-IOF - FINAL PROGRAMME

### 11.30-11.40 OC8

*Risedronate reduces cortical structural decay during menopause, probably by reducing intracortical porosity*  
- [E. Seeman](#), [R. Chapurlat](#), [D. Felsenberg](#), [R. Rizzoli](#)

### 11.40-11.50 OC9

*Effects of the cathepsin K inhibitor, ONO-5334, on BMD as measured by 3D QCT in the hip and the spine after 12 months treatment* - [K. Engelke](#), [S. Nagase](#), [T. Fuerst](#), [R. Eastell](#), [H.K. Genant](#), [M. Small](#), [T. Kuwayama](#), [S. Deacon](#)

### 12.15-13.45 Lunch Symposium - Rottapharm (Auditorium 1)

### 12.15-13.45 Lunch Symposium - Pfizer (Auditorium 2)

### 13.45-15.00 Poster Session I (P101 to P399) & Exhibition Viewing (Poster Area - 2<sup>nd</sup> Floor)

### 14.00-15.00 ESCEO-FROMO Symposium (ESCEO room 2 - 1<sup>st</sup> floor)

#### **Long-term treatment of osteoporosis**

**Chairmen:** [R. Rizzoli](#) and [C. Cooper](#)

- Welcome - [J.-Y. Reginster](#)
- Long-term treatment with calcium and vitamin D - [R. Rizzoli](#)
- Long-term treatment with selective estrogen receptor modulators - [M. Diaz Curiel](#)
- Long-term treatment with bisphosphonates - [R. Lorenc](#)
- Long-term treatment with strontium ranelate - [B. Cortet](#)
- Discussion - [S. Epstein](#), [J.-Y. Reginster](#)

### 14.00-15.00 ESCEO-FROMO Symposium (ESCEO room 1 - 1<sup>st</sup> floor)

#### **How should partial adherence be taken into account in health economic models in osteoporosis?**

**Chairmen:** [M. Hilgsmann](#) - [J.A. Kanis](#)

- Welcome and introduction - [J.-Y. Reginster](#)
- Basing adherence on empirical observations and how does partial adherence impact on anti-fracture efficacy  
- [M. Hilgsmann](#) and [V. Rabenda](#)
- Impact of adherence on health economic assessment in post-menopausal osteoporosis - [J.A. Kanis](#)
- Discussion - [J.A. Kanis](#), [S. Corcaud](#), [V. Rabenda](#), [E. Badamgarav](#), [M. Hilgsmann](#), [S. Korte](#), [W. Dere](#), [B. Mitlak](#), [P. Alegre](#), [J.-Y. Reginster](#).

### 14.00-15.00 Educational Lecture (Auditorium 2)

**How to monitor anti-osteoporosis treatments at the individual level?** - [S. Papapoulos](#)

### 14.00-15.00 Meet the Professor Sessions (1<sup>st</sup> floor)

- Treatment strategy: how long to treat - [J.P. Bilezikian](#) (MTP room 1 - 1<sup>st</sup> floor)
- Guidelines for the management of osteoarthritis - [O. Bruyère](#) (MTP room 2 - 1<sup>st</sup> floor)
- Vitamin D: when and how much? - [B. Dawson-Hughes](#) (MTP room 3 - 1<sup>st</sup> floor)
- Update on renal osteodystrophy - [P. Miller](#) (MTP room 4 - 1<sup>st</sup> floor)

### 14.15 -14.45 Oral Presentation of Selected Posters

**Moderator:** [E. Seeman](#)

### 14.15-14.20 P101

*Systematic follow up of fragility fracture: preliminary results of a multidisciplinary approach*

[J. Delisle](#), [J. Fernandes](#), [Y. Troyanov](#), [S. Perreault](#)

### 14.20-14.25 P134

*Improvement in muscle power, muscle function and back pain in elderly GIOP patients by combined therapy with alfacalcidol and alendronate*

[J. Ringe](#), [E. Schacht](#), [L.t Dukas](#), [Z. Mazor](#)

### 14.25-14.30 P159

*Does birthweight predict bone mass in adulthood? A systematic review and meta-analysis*

[J. Baird](#), [M. Asim Kurshid](#), [M. Kim](#), [N. Harvey](#), [E. Dennison](#), [C. Cooper](#)

### 14.30-14.35 P214

*Effect of once-yearly zoledronic acid in men after recent hip fracture: results from horizon recurrent fracture trial*

[S. Boonen](#), [J.-M. Kaufmann](#), [E. Orwoll](#), [J. Magaziner](#), [C. Colon-Emeric](#), [R. Adachi](#), [C. Bucci-Rechtweg](#), [P. Haentjens](#), [D. Vanderschueren](#), [K. Lyles](#)

### 14.35-14.40 P553

*Consumption of fermented milk containing blueberry, enriched with calcium and vitamin D positively modulates bone metabolism in postmenopausal women*

[C. Puel](#), [M.-J. Davicco](#), [P. Lebecque](#), [V. Coxam](#)

### 14.40-14.45 P257

*Obesity and fractures: a population-based study using the SIDIAP database*

[D. Prieto-Alhambra](#), [F. Fina Aviles](#), [E. Hermosilla](#), [A. Pages-Castella](#), [R. Guerri](#), [X. Nogues](#), [A. Diez-Perez](#)

### 15.00-16.45 Scientific Session II (Auditorium 1)

**Chairs:** [H. Orimo](#) - [J.-P. Bilezikian](#)

### 15.00-15.30 Plenary Lecture 3

**Pathophysiological basis of osteonecrosis of the jaw and atypical fractures** - [J. Compston](#)

### 15.30-16.45 Oral Communications

### 15.30-15.40 OC10

*Incidence and demography of femur fractures with and without atypical features in the Pacific Northwest (NW) United States of America (USA)* - [A. Feldstein](#), [M. Rix](#), [E. Orwoll](#),

[D. Black](#), [N. Perrin](#), [A. Rosales](#), [D. Friess](#), [D. Boardman](#), [R. Dell](#), [A.Santora](#), [J. Chandler](#)

### 15.40-15.50 OC11

*Bisphosphonate use is associated with reduced revisions of lower limb joint (knee or hip) arthroplasty: a population-based cohort study* - [D. Prieto-Alhambra](#), [M.K. Javaid](#), [A. Judge](#),

[D.W. Murray](#), [A.J. Carr](#), [C. Cooper](#), [N.K. Arden](#)



## 15.50-16.00 OC12

*Superior effects of strontium ranelate compared to alendronate on bone mass and strength parameters at the tibia in women with post menopausal osteoporosis* - D. Felsenberg, M.L. Brandi, G. Sergi, I. Bergström, G. Beller, C. Fiore, G. Lyritis, A. Kindmark, H. Boerst, O. Bock, M. Hartard, M. Runge

## 16.00-16.10 OC13

*Hemiarthroplasty cost effective in the treatment of femoral neck fractures in the elderly: a cost utility analysis of 2 years of hemiarthroplasty and internal fixation of displaced femoral neck fractures in 166 patients* - F. Frihagen, G. Waaler, J.E. Madsen, L. Nordsletten, E. Aas

## 16.10-16.20 OC14

*Quality of life four months following a fracture. Results from the ICUROS* - F. Borgström, K.Sanders, T. Thomas, I. Lekander, O. Ström, V. Alekna, M.L. Bianchi, P. Clark, M. Díaz Curiel, H.P. Dimai, O. Lesnyak

## 16.20-16.30 OC15

*Denosumab reduces the risk of clinical osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®* - E. McCloskey, M. Lewiecki, J.A. Kanis, H. Johansson, A. Oden, M. Austin, E. Siris, A. Wang, C. Libanati, R. Chapurlat, R. Lorenc

## 16.30-16.40 OC16

*Bone formation is significantly greater in women on strontium ranelate than in those on alendronate after 6 and 12 months of treatment: histomorphometric analysis from a large randomized controlled trial* - P. Chavassieux, K. Brixen, C. Zerbin, R. Pereira, P. De La Peña, I. Valter, T. Hala, P. Novosad, J. Zanchetta, Z. Man, L.G. Ste-Marie, P.J. Meunier, R. Chapurlat

## 17.00-18.30 Satellite Symposium - Servier (Auditorium 1)

## 17.00-18.30 Satellite Symposium - MSD (Auditorium 2)

## FRIDAY MARCH 25

### 09.00-11.50 Scientific Session III (Auditorium 1)

**Chairs:** E. Seeman - R. Lederman

### 09.00-09.30 Plenary Lecture 4

***Osteoporosis treatments and fracture healing*** - J. Goldhahn

### 09.30-10.00 Oral Communications

#### 09.30-09.40 OC17

*Nitroglycerin improves bone mineral density, bone geometry and bone strength: results from a two-year randomized controlled trial* - S. Jamal, C. Hamilton, R. Eastell, S. Cummings

#### 09.40-09.50 OC18

*The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (vital D study) for falls and fractures in older women* - K. Sanders, A. Stuart, E. Williamson, J. Simpson, M. Kotowicz, G. Nicholson

#### 09.50-10.00 OC19

*Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology* - J. Koh, S.K. Goh, M.A. Png, A. Ng, T.S. Howe

### 10.00-10.30 Plenary Lecture 5

***FRAX, 2 years after its launch*** - E. McCloskey

### 10.30-11.50 Oral Communications

#### 10:30-10:40 OC20

*Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5mg* - D. Black, I. Reid, R. Eastell, C. Bucci Rechtweg, G. Su, T.F. Hue, K. Lyles, S. Boonen

#### 10.40-10.50 OC21

*Fractures in obese postmenopausal women: prevalence, skeletal location and risk factors* - J. Compston, J. Netelenbos, R. Lindsay, C. Cooper, A. Diéz-Pérez, S. Greenspan, F. Hooven, A. LaCroix, M. Rossini, J. Flahive

#### 10.50-11.00 OC22

*Methylation status of the RXRA promoter in umbilical cord predicts childhood bone mineral content* - N. Harvey, H. Inskip, B. Emerald, C. Gale, M. Hanson, P. Gluckman, K. Godfrey, C. Cooper, E. Garratt, A. Sheppard, C. McLean, K. Lillycrop, G. Burdge, J. Slater-Jefferies, J. Rodford, S. Crozier

#### 11.00-11.10 OC23

*Risk factors predictive of joint replacement in a two-year multicentre clinical trial in knee osteoarthritis using MRI: results from over six years of observation* - J-P. Raynaud, J. Martel-Pelletier, B. Haraoui, D. Choquette, M. Dorais, L. Wildi, F. Abram, J-P. Pelletier

#### 11.10-11.20 OC24

*Sclerostin plays a key role in abnormal Wnt/ $\beta$ -catenin signaling in human osteoarthritic subchondral osteoblasts leading to reduced mineralization* - E. Abed, D. Couchourel, A. Delalandre, J. Martel-Pelletier, J-P. Pelletier, D. Lajeunesse



## ECCEO11-IOF - FINAL PROGRAMME

### 11.20-11.30 OC25

*Five-year denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the FREEDOM trial extension* - S. Papapoulos, Z. Man, D. Mellstrom, S. Radominski, J.-Y. Reginster, H. Resch, J. Román, C. Roux, S. Cummings, H. Bone, R. Chapurlat, M. Brandi, J. Brown, E. Czerwinski, N. Daizadeh, A. Grauer, M.-A. Krieg, C. Libanati

### 11.30-11.40 OC26

*Poor cortical bone status in men with elevated concentrations of osteoprotegerin - the STRAMBO study* - P. Szulc, G. Hawa, S. Boutroy, N. Vilayphiou, M. Schoppet, R. Chapurlat, L. Hofbauer

### 11.40-11.50 OC27

*In balloon kyphoplasty for osteoporotic vertebral body fractures, the potentiation of reduction is depending on the time to surgery* - T. Blattert, C. Günther, S. Glasmacher, C. Josten

### 12.15-13.45 Lunch Symposium - Amgen (Auditorium 1)

### 12.15-13.45 Lunch Symposium - Medtronic (Auditorium 2)

### 13.45-15.00 Poster Session II (P400 to P688)

### & Exhibition Viewing (Poster Area - 2<sup>nd</sup> Floor)

### 14.00-15.00 ESCEO-FROMO Symposium

#### (ESCEO Room 1 - 1<sup>st</sup> floor)

**Recommendations for the design of clinical trials to be conducted by food and food supplements, in order to be granted the right to use health claims in osteoporosis** (in collaboration with GREES)

**Chairmen:** R. Rizzoli and O. Bruyère

- Welcome - J.-Y. Reginster
- *Why do we need guidelines before granting health claims authorization to food supplement?* - V. Coxam
- *Regulatory approach of health claims for food supplements in Europe* - A. Martin
- *Health claims in osteoporosis for food supplements*
  - O. Bruyère
- Discussion - B. Avouac

### 14.00-15.00 ESCEO-FROMO Symposium

#### (ESCEO Room 2 - 1<sup>st</sup> floor)

**Generic versus branded medication in osteoporosis: Are they really similar?** - **Chairmen:** Rick Adachi - J.A. Kanis

- Welcome and introduction - J.A. Kanis
- *Generic medications: definition and regulatory aspects in Europe* - J.-M. Kaufman
- *Brand versus generic bisphosphonates: are they equally effective and tolerated* - J. Ringe
- *Brand versus generic bisphosphonates: implications for patient management* - R. Adachi
- Discussion - C. Cooper, J.-M. Kaufman, J. Ringe, R. Adachi, M. Hiligsmann, J.A. Kanis, J.-Y. Reginster
- Conclusion - J.A. Kanis.

### 14.00-15.00 Meet the Professor Sessions

- *Osteoporosis in children and adolescents* - E. Seeman (MTP Room 1 - 1<sup>st</sup> floor)
- *Practical use of vertebral fracture assessment* - H. Genant (MTP Room 2 - 1<sup>st</sup> floor)
- *Osteoporosis Management after a fracture* - S. Boonen (MTP Room 3 - 1<sup>st</sup> floor)
- *Bone effects of biologicals for rheumatoid arthritis* - J. Louie (MTP Room 4 - 1<sup>st</sup> floor)

### 14.15-14.45 Oral Presentation of Selected Posters

**Moderator:** E. Seeman

### 14.15-14.20 P325

*Effect of oral ibandronate on bone microarchitecture in women with osteopenia: a randomized placebo-controlled trial*  
R. Chapurlat, M. Laroche, T. Thomas, S. Rouanet, P. Delmas, M.-C. De Vernejoul

### 14.20-14.25 P385

*A comparison of case-finding strategies for the management of osteoporosis*

E. McCloskey, H. Johansson, J. Compston, A. Oden, J. Kanis

### 14.25-14.30 P415

*Meta-analysis of genome-wide association studies for quantitative ultrasound of the heel: the gefos consortium*  
A. Moayyeri, N. Wareham, P. Sham, C. Hayward, U. Gyllenstein, H. Campbell, A. Uitterlinden, T. Spector, A. Kung, D. Kiel, F. Rivadeneira, Y.-H. Hsu, D. Karasik, J. Reeve, Stephen Kaptoge, K. Estrada, S. Brown, S. Xiao, W. Igl, O. Polasek, S. Wilson, K.-T. Khaw

### 14.30-14.35 P420

*Increased fat mass is associated with increased bone size but reduced volumetric density in pre pubertal children*  
Z. Cole, N. Harvey, M.a Kim, S. Robinson, H. Inskip, K. Godfrey, C. Cooper, E. Dennison

### 14.35-14.40 P256

*Positive impact of both protein intake and physical activity before puberty on biomechanical strength at weight bearing skeletal sites 7.8 yrs later in healthy boys* - T. Chevalley, J.-P. Bonjour, B. Van Rietbergen, S. Ferrari, R. Rizzoli

### 14.40-14.45 P151

*Incidence of hip fracture in Belgium between 2000 and 2007 and future projections*

M. Hiligsmann, O. Bruyère, J. Detilleux, P. Gillet, Y. Parmentier, J.-P. Dercq, J. Carton, J.-Y. Reginster

### 15.00-16.45 Scientific Session IV (Auditorium 1)

**Chairs:** G. Riera - J. Adachi

### 15.00-15.30 Plenary Lecture 6

**Epidemiology and outcome of lower limb osteoarthritis and arthroplasty** - C. Cooper



## 15.30-16.45 Oral Communications

### 15.30-15.40 OC28

*Dynamic PET/CT imaging with L-[methyl-<sup>11</sup>C]methionine after resistance exercise: a novel biomarker of skeletal muscle protein synthesis?* - T. Lang, M. Hernandez-Pampaloni, R. Hawkins, Y. Seo, G. Sayre, R. Harnish, T. Streeper, I. Saeed, C. Schreck, S. Dannoon, J. Slater, J. Blecha, H. VanBrocklin

### 15.40-15.50 OC29

*PTH efficacy in bone healing models with T-cell deficient rats* - M. Sato, M. Adrian, M. Hamang, A. Harvey, Q. Zeng, Y. Ma

### 15.50-16.00 OC30

*Intermediate molecular weight hyaluronic acid (GO-ON) is superior to the low molecular weight standard preparation (Hyalgan) in symptom control of knee osteoarthritis over 6 months* - F. Berenbaum, E. Maheu, J. Grifka, S. Cazzaniga, M. D'Amato, G. Giacobelli, X. Chevalier, F. Rannou, P. Ravaud, L. Rovati

### 16.00-16.10 OC31

*LRP5 gene polymorphisms contribute to the heritability of trabecular bone structure* - S. Ferrari, T. Chevalley, J.-P. Bonjour, R. Rizzoli

### 16.10-16.20 OC32

*Long-term efficacy and safety of strontium ranelate in postmenopausal osteoporotic women: results over 10 years* - J.-Y. Reginster, J.M. Kaufman, J.-P. Devogelaer, C.L. Benhamou, C. Roux

### 16.20-16.30 OC33

*Updating of fracture incidence rates for the italian version of FRAX®* - P. Piscitelli, M.L. Brandi

### 16.30-16.40 OC34

*The effects of rosiglitazone on bone by multiple image modalities in postmenopausal women with type 2 diabetes mellitus* - L. Fitzpatrick, B. Kravitz, A. Northcutt, G. Paul, A. Cobitz, A. Nino

## 17.00-18.30 ESCEO-FROMO Symposium

(ESCEO Room 2 - 1<sup>st</sup> floor)

### **Frailty and Sarcopenia: State of the art**

**Chairmen:** R. Rizzoli - J.A. Kanis

- Welcome and introduction - J.-Y. Reginster
- Definition of frailty syndrome - C. Cooper
- Epidemiology of frailty syndrome - A.A. Sayer
- Pathophysiology of physical frailty: Inflammatory mechanisms - C. Sieber
- Pathophysiology of physical frailty: Hormonal mechanisms - J.-M. Kaufman
- Methodology of evaluation of Sarcopenia and Frailty - G. Abbelan van Kan
- Future pathway for registering therapeutics in Sarcopenia and Frailty - W.J. Evans
- Discussion - J. A. Kanis, R. Rizzoli, J.-M. Kaufman, C. Cooper, A.A. Sayer, C. Sieber, G. Abbelan van kan, W. J. Evans, R. Adachi, S. Boonen, W. Dere, B. Mitlak, Y. Tsouderos, J.-Y. Reginster

## SATURDAY MARCH 26

### 09.00-11.50 Scientific Session V (Auditorium 1)

**Chairs:** B. Masri - U. Liberman

### 09.00-09.30 Plenary Lecture 7

**Frailty and muscle metabolism dysregulation in the elderly** - W. Evans

### 09.30-10.00 Oral Communications

#### 09.30-09.40 OC35

*Antifracture efficacy and safety of once-yearly zoledronic acid 5 mg in men with osteoporosis: a prospective, randomized, controlled trial* - S. Boonen, G. Su, E. Incera, E. Orwoll, J.-M. Kaufman, J.-Y. Reginster, R. Rizzoli, K. Lippuner, D. Vanderschueren, C. Bucci-Rechtweg, O. Antunez, P. Papanastasiou

#### 09.40-09.50 OC36

*Cost-effectiveness of denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women* - M. Hilgsmann, J.-Y. Reginster

#### 09.50-10.00 OC37

*Use of microarray technology to support development of nutraceutical supplements to reduce bone resorption and enhance bone formation* - Y. Lin, S. Ramakrishnan, V. Kazlova, M. Murray, D. Fast, K. Gellenbeck, A. Chandra

### 10.00-10.30 Plenary Lecture 8

**Emergent therapies in osteoporosis** - S. Papapoulos

### 10.30-11.50 Oral Communications

#### 10.30-10.40 OC38

*Four-year results of a phase 2 study of the cathepsin K inhibitor odanacatib in postmenopausal women with low bone mineral density: effects on bone turnover markers* - S. Papapoulos, J. Rodriguez Portales, R. Petrovic, E. Rosenberg, C. DaSilva, A. Santora, A. Lombardi, N. Binkley, H. Bone, J. Eisman, D. Hosking, B. Langdahl, M. McClung, I. Reid, H. Resch

#### 10.40-10.50 OC39

*Helicobacter pylori Cag-A positive strains negatively affect bone health: a population based study* - L. Gennari, G. Martini, R. Nuti, N. Figura, D. Merlotti, M.S. Campagna, M.B. Franci, A. Avanzati, B. Lucani, A. Calabrò, S. Lardiello

#### 10.50-11.00 OC40

*Mortality risk for operated and non-operated vertebral fracture patients in the U.S. Medicare population* - A. Edidin, K. Ong, E. Lau, S. Kurtz

#### 11.00-11.10 OC41

*Efficacy and safety of strontium ranelate in the treatment of male osteoporosis* - J.M. Kaufman, J.-D. Ringe, D. Felsenberg, M. Audran, G. Bianchi, S. Boonen, R. Josse, R.M. Francis, S. Goemaere, S. Palacios, M. Diaz Curiel



## ECCEO11-IOF - FINAL PROGRAMME

### 11.10-11.20 OC42

*Comparing effects of kyphoplasty, vertebroplasty and nonsurgical management in a meta-analysis of randomized and nonrandomized controlled studies* - I. Papanastassiou, F. Phillips, J. Van Meirhaeghe, J. Berenson, G. Andersson, G. Chung, C. Danilov, B. Small, F. Vronis

### 11.20-11.30 OC43

*Association between vitamin-D receptor gene polymorphisms with the risk of fractures among Saudi postmenopausal women* - M-S. Ardawi, A. Rouzi, W. Faqeeh, S. Al-Sibiani, N. Al-Senani, H. Sonbol, R. Raddadi

### 11.30-11.40 OC44

*Periostin, a matricellular glutamic-acid protein influences crosslinking of bone collagen* - E. Gineyts, N. Bonnet, S. Ferrari, P. Garnero

### 11.40-11.50 OC45

*BMD and BMC improvements in hip total, trabecular, and cortical bone following denosumab treatment: QCT results from the FREEDOM trial* - H. Genant, H. Radcliffe, C. Libanati, K. Engelke, J. Zanchetta, A. Høiseth, C. Yuen, S. Stonkus, M. Bolognese, E. Franek, T. Fuerst

### 12.15-13.45 Lunch Symposium - Danone (Auditorium 2)

#### 12.15-13.45 ESCEO-FROMO Symposium (ESCEO Room 2 - 1<sup>st</sup> Floor)

##### **Bone repair with anti-osteoporosis medications**

**Chairmen:** J. Goldhahn - J.A. Kanis

- Welcome and introduction - J.-Y. Reginster
- Bone repair: Facts and challenges - J. Goldhahn
- Preclinical evaluation of bone repair - J. Goldhahn
- Osteoporosis treatment and fracture healing - Clinical evidence - S. Boonen
- Discussion - J. Goldhahn, S. Boonen, B. Mitlak, J.M. Feron, W. Dere, S. Papapoulos, Y. Tsouderos, J.A. Kanis, J.-Y. Reginster

#### 14.00-15.30 ESCEO-FROMO Symposium

(ESCEO Room 2 - 1<sup>st</sup> Floor)

##### **Adverse reactions and drug-drug interactions in the management of osteoporosis**

**Chair:** A. Diez-Perez - R. Rizzoli

- Welcome - J.-Y. Reginster
- Bisphosphonates: Adverse Reactions and Drug-Drug Interactions - C. Cooper
- SERMs: Adverse Reactions and Drug-Drug Interactions - J.-M. Kaufman
- Strontium Ranelate: Adverse Reactions and Drug-Drug Interactions - G. Breart
- Teriparatide: Adverse Reactions and Drug-Drug Interactions - A. Diez-Perez
- Denosumab: Adverse Reactions and Drug-Drug Interactions - D. Felsenberg
- Discussion Leader - A. Diez-Perez
- Summary of the ESCEO working group guidance - C. Cooper

### 14.00-15.00 Meet the Professor Sessions

- How to improve adherence in osteoporosis - E. Dennison (MTP Room 1 - 1<sup>st</sup> floor)
- Health economics analyses in osteoporosis: from theory to practice - M. Hilgsmann (MTP Room 2 - 1<sup>st</sup> floor)
- Muscle weakness, frailty and falls - W. Evans (MTP Room 3 - 1<sup>st</sup> floor)
- Post-transplantation osteoporosis - S. Epstein (MTP Room 4 - 1<sup>st</sup> floor)

### 15.00-16.30 Meetings of the National Scientific Societies - OA Symposium (Auditorium 2)

- Welcome and introduction - J.-Y. Reginster (Chairman)
- New proposal in the classification of OA - G. Herrero-Beaumont
- Vision of OA from the point of view of the rheumatologist and orthopaedic surgeon - P. Benito & Dr. Maculé
- Update on Diacerein - A. Gracia
- Discussion and conclusions

## GENERAL PUBLIC MEETING

Thursday 24 March (Hotel Medium Valencia)

16.00-18.00

### **Osteoporosis: the importance of looking after the bones day by day**

**Chairmen:** M. Díaz Curiel and A. Díez Pérez

- Osteoporosis and its risk - J. Calvo Catalá, J.J. García Borrás
- Diagnosis: when to consult, role of different specialists - F. Gomar
- Healthy-bone life: food and physical activity - V. Giner
- Questions and debate

## CONFERENCE FOR RHEUMATOLOGIC PATIENTS: FOCUS ON OSTEOARTHRITIS

Saturday 26 March (Hotel Sorolla Palace)

12.00

- Osteoarthritis reality and its treatment - R. Lluch
- The role of patients' associations: LIRE - B. Martos (President of LIRE)

## GENERAL PRACTITIONERS SESSION (OSTEOPOROSIS WORKING GROUP OF THE SPANISH SOCIETY OF GPs)

Saturday 26 March (Palacio de Congresos, room TBC)

16.00-18.00

**Chairman:** M. Díaz Curiel

- The GPs vision of the osteoporosis clinical practice - J. San Félix
- Clinical cases presentation - C. Carbonell, C. Valdés